Cytiva - formerly GE Healthcare Life Sciences

Ring Vägbeskrivning

Cytiva - formerly GE Healthcare Life Sciences Our mission is to advance and accelerate future therapeutics

11/08/2026

Why are approvals getting faster?​

In this clip from our conversation with Rick Berke and Cytiva's Zock Zamaniyan at BIO International, Zock shares what he's seeing: expanded expedited pathways, more first-cycle approvals, and less regulatory rework.​
The result? Less friction getting promising therapies through the process.​

Watch the full panel discussion here: https://okt.to/7KUyOW

07/08/2026

The next challenge in ADC development may not be finding more candidates. It may be understanding them better, earlier.​

As ADC programs advance, understanding complex molecular interactions can be critical to making confident development decisions.​

SPR provides real-time insights into affinity and kinetics, helping teams characterize complex interactions, reduce uncertainty, and make more informed decisions earlier in the development journey.​

Discover how SPR can help characterize complex ADC interactions: https://okt.to/jvHlVT​

05/08/2026

Reliable aseptic filling starts long before a vial reaches the line. It begins with how the system is built, and with the people who build it.​

In From design to delivery: SA25 aseptic filling workcell at INITS, we close the story with Neil Fulgueras and Michael Friesen, who offer a behind-the-scenes look at our Burnaby site. Each SA25 is assembled from more than 4,000 parts, following defines processes that help ensure every unit performs the way customers expect.​

Their work shows how careful assembly and attention to detail translate into dependable filling systems.​

👉 Explore our aseptic filling solutions: https://okt.to/e0Hq4W ​
🎥 See the full story here: https://okt.to/kT85Pl

03/08/2026

🔬 Blocked again: the most underestimated step in Western blotting.

High background, weak signal, or poor reproducibility often trace back to one step we tend to rush: blocking.

In our latest article: Block smarter, blot better, we break down the core principles behind effective Western blot blocking.

Blocking - because your antibodies deserve boundaries.

Read the full article 👉https://okt.to/n9uQVH

29/07/2026

Is your research approach keeping pace with next-generation therapeutics? ​
​
At DiPIA 2026, speakers from across academia and industry will share how SPR is being applied to some of today’s ​most complex research challenges.​
​
Across the program, the science spans from modern drug discovery workflows and cancer immunotherapy, through ​molecular recognition and biosimilar analytics, to the realities of manufacturability, CMC, and quality control.​
​
Scientists and researchers from organizations including Novartis, AbbVie, Roche, Merck Life Science, Novo Nordisk, and Bristol Myers Squibb will share practical perspectives across these areas.​
​
📅 Explore the agenda: https://okt.to/LIxUwd​
📍 Berlin | October 2026​
​
Join us to help shape the future of molecular interaction analysis.​
​

27/07/2026

A new phase for genomic medicine is taking shape.​

Across the field, scientists are working to expand access to the therapeutic toolbox – for drug developers, clinicians, and ultimately, patients.​

As in vivo approaches continue to evolve, the potential is clear. But so are the challenges.​

What will it take to make these innovations more accessible and scalable in practice?​

Where do you see the biggest opportunities or challenges? Share your perspective in the comments.​

20/07/2026

Adding new filling capacity requires more than equipment, it requires clarity. Teams need to know what to expect: timelines, key steps, and how the system will fit into their operations.​

In From design to delivery: SA25 aseptic filling workcell at INITS, we continue the story with Scott Harper, who shares how having a clear, repeatable delivery process made planning easier for INITS. Scott also notes what many customers look for: flexibility, consistent results, and a straightforward path as they move toward clinical production. ​
His insight highlights something we hear across the industry: predictability matters.​

👉 Explore our aseptic filling solutions https://okt.to/X4FAjE ​
🎥 See the full story here: https://okt.to/GDHAVq

15/07/2026

More than 20 phage therapy clinical trials were underway in 2025.​

The question is no longer whether bacteriophages are therapeutically interesting. It's whether they can be manufactured consistently enough to reach more patients.​

That's the challenge being explored through PHOENIX – a collaboration between Biofactory Competence Center, CRISP - Centre de recherche et d’innovation en sciences pharmaceutiques cliniques CHUV and Cytiva, focused on developing scalable purification approaches for therapeutic bacteriophages.​

In this video, an ÄKTA flux s arrives at BCC, where it will support tangential flow filtration (TFF) steps within the project.​

It's an exciting example of academia, healthcare and industry working together to tackle some very real process development challenges.​

https://okt.to/qfxAXh

The body has the potential to become the place where therapies are created, not just delivered.​This shift points to a n...
10/07/2026

The body has the potential to become the place where therapies are created, not just delivered.​

This shift points to a new way of thinking about how medicines are developed. It moves away from complex external manufacturing and toward enabling therapies to be created within the patient.​

As genomic medicine advances, expanding access to the therapeutic toolbox for developers, clinicians, and patients will be key.​

What role do you see in vivo approaches playing in that future?​

🎥 Watch "Episode 1: The vision" – part of our "The body as a bioreactor" video series here: https://okt.to/6kJR2X

With the FDA’s 2025 guidance placing greater emphasis on comparative analytical data, the bar for binding characterisati...
06/07/2026

With the FDA’s 2025 guidance placing greater emphasis on comparative analytical data, the bar for binding characterisation just got higher. It’s no longer enough to show that biosimilar binds; regulators want to understand how it binds too.​

Biacore SPR technology supports this shift by providing real-time, label‑free kinetic data aligned with today’s regulatory expectations, including:​

✅ Binding kinetics and affinity to confirm similar target engagement ​
✅ Fc receptor interactions relevant to mechanism of action and safety ​
✅ Impact of post‑translational modifications (PTMs) such as glycosylation or charge variants​
✅ Sensorgram‑derived kinetic profiles for biosimilar and reference comparison​

Together, these capabilities help reduce uncertainty and strengthen regulatory submissions.

Read the whitepaper to learn how Biacore SPR systems support biosimilar development and validation worldwide. https://okt.to/iGNZwR

Adress

Björkgatan 28
Uppsala
75323

Telefon

+46771400600

Webbplats

Aviseringar

Bli först med att veta: vi skickar ett mejl när Cytiva - formerly GE Healthcare Life Sciences publicerar nyheter och kampanjer. Din e-postadress används inte till något annat, och du kan avsluta prenumerationen när som helst.

Genvägar

Dela

Kategori